A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Phase 2
204
about 3.1 years
18–75
18 sites in AZ, CT, FL +7
About this study
This trial is testing a treatment called SAR441566 for people with ulcerative colitis. The goal is to see if this treatment helps improve symptoms and is safe to use. Participants will receive either SAR441566 or a placebo (inactive pill) for up to 52 weeks, along with an optional open-label period.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take SAR441566
- 2.Take SAR441566 matching Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: Change from baseline in PRO2 from randomization to Week 12, Number of participants with any treatment-emergent adverse events (TEAEs) during induction and maintenance treatment period, Number of participants with any treatment-emergent adverse events (TEAEs) during open-label treatment period, Proportion of participants achieving the combination of patient-reported outcome 2 (PRO2) remission and endoscopic remission at Week 12
Gastroenterology